retatrutide maximum dose clinical trials in adults with obesity over 104 weeks in the highest group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide dose schedule: complete week-by-week

Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment

Fatty Acid Acylation and Albumin Binding Pharmacokinetics Source: PubMed PMID: 26308095 Summary: This medicinal chemistry study described the design and structure-activity relationships of GLP-1 analogs with C-18 fatty diacid modifications

Avoid large portions, high-fat foods during peak nausea, and hot foods when nauseated

This solid foundation supports long-term progress and injury prevention

Frequently Asked Questions (FAQs) Q1: What are the most common GLP-1 side effects